Profile data is unavailable for this security.
About the company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
- Revenue in USD (TTM)3.74bn
- Net income in USD-677.35m
- Incorporated2019
- Employees6.77k
- LocationBiontech SEAn der Goldgrube 12MAINZ 55131GermanyDEU
- Phone+49 49 613190840
- Fax+49 61 319084390
- Websitehttps://www.biontech.com/
Mergers & acquisitions
| Acquired company | 22UA:GER since announced | Transaction value |
|---|---|---|
| Curevac NV | -4.02% | 1.55bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regencell Bioscience Holdings Ltd | 0.00 | -3.58m | 15.44bn | 12.00 | -- | 3,176.36 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.0098 | 0.00 | -- | -- | 0.00 | -50.50 | -53.93 | -53.75 | -65.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.68 | -- | 5.32 | -- |
| Revolution Medicines Inc | 0.00 | -960.98m | 18.62bn | 809.00 | -- | 11.44 | -- | -- | -5.18 | -5.18 | 0.00 | 8.42 | 0.00 | -- | -- | 0.00 | -47.87 | -28.38 | -52.53 | -30.68 | -- | -- | -- | -1,324.37 | -- | -- | 0.1384 | -- | -100.00 | -- | -37.52 | -- | 31.83 | -- |
| Exact Sciences Corp | 3.25bn | -207.95m | 19.71bn | 7.10k | -- | 8.20 | 1,437.96 | 6.07 | -1.10 | -1.10 | 17.21 | 12.58 | 0.5509 | 5.99 | 11.86 | 457,322.50 | -3.53 | -8.66 | -3.99 | -9.54 | 69.69 | 70.20 | -6.40 | -21.53 | 2.17 | -- | 0.4935 | -- | 17.69 | 16.84 | 79.79 | -- | -15.13 | -- |
| BioNTech SE - ADR | 3.74bn | -677.35m | 27.38bn | 6.77k | -- | 1.16 | -- | 7.33 | -2.79 | -2.79 | 15.59 | 91.06 | 0.1441 | 1.71 | 3.74 | 551,642.20 | -2.61 | 26.29 | -2.93 | 30.47 | 85.62 | 83.89 | -18.13 | 46.16 | 7.02 | -- | 0.0131 | 4.85 | -27.96 | 90.87 | -171.51 | -- | 44.79 | -- |
| Iqvia Holdings Inc | 16.31bn | 1.36bn | 28.31bn | 91.00k | 21.25 | 4.35 | 11.40 | 1.74 | 7.86 | 7.86 | 93.98 | 38.34 | 0.5739 | -- | 4.94 | -- | 4.71 | 4.69 | 6.47 | 6.14 | 33.29 | 34.29 | 8.21 | 8.18 | -- | 3.36 | 0.7034 | -- | 5.87 | 7.50 | -0.9468 | 37.27 | -0.4257 | -- |
| Insmed Inc | 447.02m | -1.18bn | 31.72bn | 1.27k | -- | 33.44 | -- | 70.97 | -6.18 | -6.18 | 2.35 | 4.45 | 0.2026 | 0.9558 | 8.31 | 351,708.90 | -53.64 | -44.83 | -63.35 | -51.79 | 76.54 | 77.08 | -264.83 | -226.78 | 4.34 | -44.87 | 0.4351 | -- | 19.17 | 21.66 | -21.91 | -- | -12.30 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 4.89m | 2.03% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2025 | 4.83m | 2.01% |
| Flossbach von Storch SEas of 31 Dec 2025 | 4.20m | 1.75% |
| PRIMECAP Management Co.as of 31 Dec 2025 | 3.80m | 1.58% |
| Dodge & Coxas of 31 Dec 2025 | 3.61m | 1.50% |
| BNP Paribas Financial Marketsas of 31 Dec 2025 | 1.58m | 0.66% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 30 Sep 2025 | 1.51m | 0.63% |
| Jane Street Capital LLCas of 31 Dec 2025 | 1.36m | 0.57% |
| Baillie Gifford & Co.as of 31 Dec 2025 | 1.24m | 0.52% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2025 | 1.13m | 0.47% |
